$XOMA
XOMA Royalty Corp

2016 Q1 Form 10-K Financial Statement

#000156459016014295 Filed on March 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q4 2015
Revenue $3.962M $48.18M $55.45M
YoY Change 49.45% 1008.42% 193.9%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.305M $4.710M $20.62M
YoY Change -17.53% 14.88% 3.8%
% of Gross Profit
Research & Development $13.61M $13.60M $70.85M
YoY Change -31.96% -29.82% -12.26%
% of Gross Profit
Depreciation & Amortization $215.0K $210.0K $1.500M
YoY Change -53.06% -54.35% -21.05%
% of Gross Profit
Operating Expenses $17.92M $18.31M $95.17M
YoY Change -28.98% -22.02% -5.49%
Operating Profit -$13.99M $28.74M -$39.72M
YoY Change -38.03% -250.25% -51.46%
Interest Expense -$1.000M -$610.0K -$3.770M
YoY Change -10.71% -39.6% -12.33%
% of Operating Profit -2.12%
Other Income/Expense, Net $5.624M -$3.389M $5.500M
YoY Change 557.78% -128.7% 166.86%
Pretax Income -$8.370M $25.35M -$20.61M
YoY Change -61.46% -446.31% -46.2%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$8.365M $25.35M -$20.61M
YoY Change -61.48% -446.42% -46.2%
Net Earnings / Revenue -211.13% 52.61% -37.16%
Basic Earnings Per Share -$1.40 $4.27 -$3.50
Diluted Earnings Per Share -$1.40 $4.24 -$3.50
COMMON SHARES
Basic Shares Outstanding 119.6M 118.8M 5.890M
Diluted Shares Outstanding 5.890M

Balance Sheet

Concept 2016 Q1 2015 Q4 2015
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.65M $66.27M $66.30M
YoY Change -30.88% -15.52% -15.43%
Cash & Equivalents $46.15M $65.77M $65.80M
Short-Term Investments $500.0K $500.0K $500.0K
Other Short-Term Assets $1.600M $1.900M $1.900M
YoY Change -15.79% 0.0% 0.0%
Inventory
Prepaid Expenses
Receivables $2.000M $3.718M $3.700M
Other Receivables $0.00 $351.0K $400.0K
Total Short-Term Assets $50.20M $72.22M $72.20M
YoY Change -30.85% -13.63% -13.64%
LONG-TERM ASSETS
Property, Plant & Equipment $1.800M $1.997M $2.000M
YoY Change -62.5% -61.0% -60.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $700.0K $664.0K $700.0K
YoY Change 0.0% -0.75% 0.0%
Total Long-Term Assets $2.400M $2.661M $2.700M
YoY Change -56.36% -54.03% -53.45%
TOTAL ASSETS
Total Short-Term Assets $50.20M $72.22M $72.20M
Total Long-Term Assets $2.400M $2.661M $2.700M
Total Assets $52.60M $74.88M $74.90M
YoY Change -32.65% -16.24% -16.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.600M $6.831M $6.800M
YoY Change 35.29% 14.04% 13.33%
Accrued Expenses $4.000M $7.400M $7.400M
YoY Change -36.51% -25.19% -26.73%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $10.20M $5.910M $5.900M
YoY Change -34.62% -68.92% -68.95%
Total Short-Term Liabilities $20.50M $23.30M $23.30M
YoY Change -22.35% -35.73% -35.64%
LONG-TERM LIABILITIES
Long-Term Debt $36.00M $42.76M $42.80M
YoY Change 13.92% 162.47% 162.58%
Other Long-Term Liabilities $3.700M $673.0K $11.10M
YoY Change -88.92% -67.16%
Total Long-Term Liabilities $39.70M $43.43M $53.90M
YoY Change -38.92% 166.61% 7.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.50M $23.30M $23.30M
Total Long-Term Liabilities $39.70M $43.43M $53.90M
Total Liabilities $60.10M $77.19M $77.20M
YoY Change -34.32% -10.56% -10.54%
SHAREHOLDERS EQUITY
Retained Earnings -$1.140B
YoY Change 1.84%
Common Stock $1.138B
YoY Change 1.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$7.500M -$2.309M -$2.300M
YoY Change
Total Liabilities & Shareholders Equity $52.60M $74.88M $74.90M
YoY Change -32.65% -16.24% -16.22%

Cashflow Statement

Concept 2016 Q1 2015 Q4 2015
OPERATING ACTIVITIES
Net Income -$8.365M $25.35M -$20.61M
YoY Change -61.48% -446.42% -46.2%
Depreciation, Depletion And Amortization $215.0K $210.0K $1.500M
YoY Change -53.06% -54.35% -21.05%
Cash From Operating Activities -$16.29M $28.77M -$30.89M
YoY Change -32.91% -265.54% -60.54%
INVESTING ACTIVITIES
Capital Expenditures $31.00K $40.00K $430.0K
YoY Change -86.22% -140.0% 32.31%
Acquisitions
YoY Change
Other Investing Activities $4.860M $4.880M
YoY Change -2.8% -75.6%
Cash From Investing Activities -$30.00K $4.900M $4.450M
YoY Change -86.96% -0.2% -77.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $171.0K
YoY Change -99.59%
Debt Paid & Issued, Net $3.271M $6.128M
YoY Change -46.23% 3.57%
Cash From Financing Activities -3.300M 80.00K 13.80M
YoY Change -124.32% -99.78% -61.19%
NET CHANGE
Cash From Operating Activities -16.29M 28.77M -30.89M
Cash From Investing Activities -30.00K 4.900M 4.450M
Cash From Financing Activities -3.300M 80.00K 13.80M
Net Change In Cash -19.62M 33.75M -12.64M
YoY Change 79.34% 38.26% -45.14%
FREE CASH FLOW
Cash From Operating Activities -$16.29M $28.77M -$30.89M
Capital Expenditures $31.00K $40.00K $430.0K
Free Cash Flow -$16.32M $28.73M -$31.32M
YoY Change -33.4% -266.26% -60.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
673000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36246000
CY2015Q4 xoma Warrant Liability
WarrantLiability
10464000
CY2014Q4 xoma Warrant Liability
WarrantLiability
31828000
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q2 dei Entity Public Float
EntityPublicFloat
451024815
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
119615729
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 dei Document Type
DocumentType
10-K
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-12-31
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65767000
CY2015Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
496000
CY2014Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
19018000
CY2014Q4 us-gaap Interest Payable Current
InterestPayableCurrent
257000
CY2014Q4 us-gaap Liabilities
Liabilities
86303000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
869000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1136881000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1121707000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1119477000
CY2013 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18477000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-124058000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-38301000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3198000
CY2015Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
5910000
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
331000
CY2014 us-gaap Contracts Revenue
ContractsRevenue
13183000
CY2015 us-gaap Contracts Revenue
ContractsRevenue
6383000
CY2015 us-gaap Revenues
Revenues
55447000
CY2015 us-gaap License And Services Revenue
LicenseAndServicesRevenue
49064000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70852000
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
42757000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
80748000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1939000
CY2014Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16290000
CY2015Q4 us-gaap Liabilities
Liabilities
77189000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
277333332
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
119045592
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
74880000
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
119045592
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0075
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.05
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1089000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23295000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
893000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1140083000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-2309000
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2015 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0000791908
CY2014 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-38300000
CY2013 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-124067000
CY2014 us-gaap License And Services Revenue
LicenseAndServicesRevenue
5683000
CY2013 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-9000
CY2014 us-gaap Operating Expenses
OperatingExpenses
100698000
CY2015 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
20620000
CY2014 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
19866000
CY2014 us-gaap Restructuring Charges
RestructuringCharges
84000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-20606000
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
117803000
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
107435000
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
117803000
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115333000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-20606000
CY2015 us-gaap Operating Expenses
OperatingExpenses
95171000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
3099000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89402000
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.05
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0075
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
277333332
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
115892450
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
115892450
CY2014 us-gaap Revenues
Revenues
18866000
CY2015 us-gaap Restructuring Charges
RestructuringCharges
3699000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-39724000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-81832000
CY2015 us-gaap Interest Expense Debt
InterestExpenseDebt
4194000
CY2014 us-gaap Interest Expense Debt
InterestExpenseDebt
4303000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5500000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2061000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-197000
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-17812000
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-45773000
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
61039000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20606000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38301000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-124072000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-14000
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.43
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.43
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86938000
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86938000
CY2014 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
21467000
CY2013 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2220000
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
82946000
CY2013 xoma Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
8348000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-3987000
CY2014 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4526000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10772000
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37786000
CY2014 xoma Increases Decreases To Additional Paid In Capital Warrant Issued
IncreasesDecreasesToAdditionalPaidInCapitalWarrantIssued
-10258000
CY2014 xoma Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
2560000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1000
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1467000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9727000
CY2015 xoma Increases Decreases To Additional Paid In Capital Warrant Issued
IncreasesDecreasesToAdditionalPaidInCapitalWarrantIssued
450000
CY2015 xoma Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
3554000
CY2015 us-gaap Depreciation
Depreciation
1532000
CY2014 us-gaap Depreciation
Depreciation
1856000
CY2013 us-gaap Depreciation
Depreciation
2575000
CY2015 xoma Defined Contribution Plan Issuance Of Common Stock For Services Or Claims
DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
986000
CY2014 xoma Defined Contribution Plan Issuance Of Common Stock For Services Or Claims
DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
870000
CY2013 xoma Defined Contribution Plan Issuance Of Common Stock For Services Or Claims
DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
828000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
9727000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
10772000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
5099000
CY2015 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1413000
CY2014 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2707000
CY2013 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2470000
CY2015 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
3505000
CY2015 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
18000
CY2013 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-281000
CY2015 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-429000
CY2015 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1870000
CY2014 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
2280000
CY2013 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-662000
CY2015 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-6000
CY2014 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-355000
CY2013 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-127000
CY2014 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
9000
CY2013 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
20000
CY2015 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
761000
CY2014 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-472000
CY2013 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-4486000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
28000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
662000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-481000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1621000
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3774000
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2901000
CY2015 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
500000
CY2013 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1671000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-45915000
CY2013 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
19991000
CY2014 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
20000000
CY2013 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
40000000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
430000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
325000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1169000
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
18000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
18840000
CY2015 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1000
CY2014 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
35000
CY2015 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
41000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13801000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
35560000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
83389000
CY2015 us-gaap Effect Of Exchange Rate On Cash Continuing Operations
EffectOfExchangeRateOnCashContinuingOperations
-37000
CY2014 us-gaap Effect Of Exchange Rate On Cash Continuing Operations
EffectOfExchangeRateOnCashContinuingOperations
-167000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-12678000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-23214000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
56314000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
101659000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45345000
CY2015 us-gaap Interest Paid
InterestPaid
1927000
CY2014 us-gaap Interest Paid
InterestPaid
3009000
CY2013 us-gaap Interest Paid
InterestPaid
1262000
CY2015 us-gaap Transfer To Investments
TransferToInvestments
496000
CY2015 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
323000
CY2015 xoma Reclassification Of Contingent Warrant Liability To Equity Exercise Of Warrants
ReclassificationOfContingentWarrantLiabilityToEquityExerciseOfWarrants
3552000
CY2014 xoma Reclassification Of Contingent Warrant Liability To Equity Exercise Of Warrants
ReclassificationOfContingentWarrantLiabilityToEquityExerciseOfWarrants
2526000
CY2013 xoma Reclassification Of Contingent Warrant Liability To Equity Exercise Of Warrants
ReclassificationOfContingentWarrantLiabilityToEquityExerciseOfWarrants
6171000
CY2015 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
450000
CY2014 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
10258000
CY2015 xoma Interest Added Principal Balances Long Term Debt
InterestAddedPrincipalBalancesLongTermDebt
327000
CY2014 xoma Interest Added Principal Balances Long Term Debt
InterestAddedPrincipalBalancesLongTermDebt
313000
CY2013 xoma Interest Added Principal Balances Long Term Debt
InterestAddedPrincipalBalancesLongTermDebt
935000
CY2013 us-gaap Noncash Or Part Noncash Acquisition Investments Acquired1
NoncashOrPartNoncashAcquisitionInvestmentsAcquired1
171000
CY2015 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Description of Business</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">XOMA Corporation (&#8220;XOMA&#8221; or the &#8220;Company&#8221;), a Delaware corporation, combines a portfolio of clinical programs and research activities to develop innovative therapeutic antibodies that it intends to commercialize. XOMA focuses its scientific research on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. XOMA&#8217;s scientific research has produced five product candidates to treat diseases within the endocrine therapeutic area.&nbsp;&nbsp;These include candidates from the XMet platform, which consists of several Selective Insulin Receptor Modulator antibodies that could offer new approaches in the treatment of metabolic diseases.&nbsp;&nbsp;The lead compound from the XMet platform, XOMA 358, is a fully human monoclonal negative allosteric modulating antibody that binds to insulin receptors and attenuates insulin action.&nbsp;&nbsp;XOMA intends to investigate this compound as a novel treatment for non-drug-induced, endogenous hyperinsulinemic hypoglycemia (low blood glucose caused by excessive insulin produced by the body). In October 2015, the Company initiated a Phase 2 proof-of-concept study for XOMA 358 in patients with congenital hyperinsulinemia.&nbsp;&nbsp;XOMA&#8217;s endocrine portfolio also includes a Phase 2 ready product candidate targeting the prolactin receptor as well as other preclinical or research stage programs.&nbsp;&nbsp;The Company&#8217;s products are presently in various stages of development and are subject to regulatory approval before they can be commercially launched.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 22, 2015, the Company announced the Phase 3 EYEGUARD-B study of gevokizumab in patients with Beh&#231;et&#8217;s disease uveitis, run by Servier, its partner for gevokizumab, did not meet the primary endpoint of time to first acute ocular exacerbation.&nbsp;&nbsp;In August 2015, XOMA announced its intention to end the EYEGUARD global Phase 3 program.&nbsp;&nbsp;In September 2015, Servier notified XOMA of its intention to terminate the Amended and Restated Collaboration and License Agreement dated February 14, 2012, as later amended on November 4, 2014 and January 9, 2015, and return the gevokizumab rights to XOMA. Termination of the collaboration agreement with Servier will be effective on March 25, 2016. As gevokizumab does not fit the Company&#8217;s strategic focus on endocrine diseases, the Company announced in March 2016 it is closing its Phase 3 study in pyoderma gangrenosum.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Management Plans</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred operating losses since its inception and had an accumulated deficit of $1.1 billion at December 31, 2015.&#160; Management expects operating losses and negative cash flows to continue for the foreseeable future.&nbsp;&nbsp;As of December 31, 2015, the Company had $66.3 million in cash, cash equivalents and marketable securities, which is available to fund future operations. Taking into account the repayment of its outstanding debt classified within current liabilities on the Company&#8217;s consolidated balance sheet as of December 31, 2015, the Company anticipates that it has adequate resources to fund its operations through December 31, 2016.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s ability to raise additional capital in the equity and debt markets, should the Company choose to do so, is dependent on a number of factors, including, but not limited to, <font style="font-family:EYInterstate Light;">the market demand for the Company&#8217;s common stock, which itself is subject to a number of pharmaceutical development and business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company.</font>&nbsp;&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:9pt;">&nbsp;</p></div>
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an on-going basis, management evaluates its estimates including, but not limited to, those related to contingent warrant liabilities, revenue recognition, debt amendments, research and development expense, long-lived assets, restructuring liabilities, legal contingencies, derivative instruments and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, such as the Company&#8217;s billing under government contracts and the Company&#8217;s accrual for clinical trial expenses. Under the Company&#8217;s contracts with the National Institute of Allergy and Infectious Diseases (&#8220;NIAID&#8221;), a part of the National Institutes of Health (&#8220;NIH&#8221;), the Company bills using NIH provisional rates and thus is subject to future audits at the discretion of NIAID&#8217;s contracting office. These audits can result in an adjustment to revenue previously reported which potentially could be significant. The Company&#8217;s accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions.</p></div>
CY2015Q4 xoma Cash And Cash Equivalents And Marketable Securities
CashAndCashEquivalentsAndMarketableSecurities
66300000
CY2014 xoma Decrease In Previously Invoiced Balances From Niaid
DecreaseInPreviouslyInvoicedBalancesFromNIAID
1800000
CY2014 xoma Changes In Accounting Estimate Related To Adjustment Accrual
ChangesInAccountingEstimateRelatedToAdjustmentAccrual
200000
CY2015 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2014 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2013 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2015Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2015Q4 us-gaap Marketable Securities
MarketableSecurities
500000
CY2014Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2015 us-gaap Availableforsale Securities Gross Unrealized Gain Loss1
AvailableforsaleSecuritiesGrossUnrealizedGainLoss1
0
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
200000
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
400000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3718000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2993000
CY2015Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
351000
CY2014Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
316000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17450000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
38628000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15453000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
33508000
CY2015Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
0
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1500000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1900000
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2900000
CY2015Q4 xoma Property And Equipment Related Cost
PropertyAndEquipmentRelatedCost
15900000
CY2015Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2609000
CY2014Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
4295000
CY2015Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2156000
CY2014Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
3061000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
517000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
409000
CY2015Q4 xoma Accrued Restructuring Costs Current
AccruedRestructuringCostsCurrent
459000
CY2015Q4 xoma Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
406000
CY2014Q4 xoma Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
1424000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
878000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
703000
CY2015 xoma Performance Deliverable Period For License And Transfer Of Technology And Knowhow
PerformanceDeliverablePeriodForLicenseAndTransferOfTechnologyAndKnowhow
P60D
CY2015 xoma Upfront Fee Recognized As Revenue
UpfrontFeeRecognizedAsRevenue
5000000
CY2015Q4 us-gaap Long Term Debt
LongTermDebt
48667000
CY2014Q4 us-gaap Long Term Debt
LongTermDebt
35308000
CY2015Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
49810000
CY2014Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
36461000
CY2015 us-gaap Restructuring Costs
RestructuringCosts
3700000
CY2015 xoma Payments For Restructuring Expenses
PaymentsForRestructuringExpenses
3200000
CY2015Q4 xoma Future Payments For Restructuring
FuturePaymentsForRestructuring
500000
CY2013Q4 xoma Accrued Restructuring Costs Current
AccruedRestructuringCostsCurrent
21000
CY2014 us-gaap Payments For Restructuring
PaymentsForRestructuring
128000
CY2014 us-gaap Restructuring Reserve Accrual Adjustment
RestructuringReserveAccrualAdjustment
23000
CY2015 us-gaap Payments For Restructuring
PaymentsForRestructuring
3240000
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
9038000
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
14677000
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
17879000
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
15664000
CY2015Q4 xoma Long Term Debt Future Principal And Final Fee Payments
LongTermDebtFuturePrincipalAndFinalFeePayments
57258000
CY2015Q4 xoma Long Term Debt Interest Final Payment Discount And Issuance Cost
LongTermDebtInterestFinalPaymentDiscountAndIssuanceCost
8591000
CY2013 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-14000
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2015 xoma Effective Income Tax Rate Reconciliation Warrant Valuation Percent
EffectiveIncomeTaxRateReconciliationWarrantValuationPercent
0.29
CY2014 xoma Effective Income Tax Rate Reconciliation Warrant Valuation Percent
EffectiveIncomeTaxRateReconciliationWarrantValuationPercent
0.40
CY2013 xoma Effective Income Tax Rate Reconciliation Warrant Valuation Percent
EffectiveIncomeTaxRateReconciliationWarrantValuationPercent
-0.17
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.15
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.01
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.00
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.48
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.73
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.17
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2015Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
50808000
CY2014Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
50852000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
115869000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5099000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
30221000
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8739000
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22926000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20606000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38301000
CY2013 xoma Defined Contribution Plan Cost Recognized And Paid Through Issuance Of Common Shares Percentage
DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage
1.00
CY2015Q4 xoma Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares To Be Issued Upon Exercise Of Options And Rs Us Outstanding
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesToBeIssuedUponExerciseOfOptionsAndRSUsOutstanding
10148543
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.60
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.49
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.27
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9727000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10772000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
105042000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
24268000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
12108000
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
18748000
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
22060000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
209693000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
190062000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
209693000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
190062000
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
19600000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
29900000
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-73900000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5503000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4274000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4104000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2687000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
720000
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
164000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1476000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
509000
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
6000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9666000
CY2015Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
8000000
CY2015 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.50
CY2015 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
18000
CY2014 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
17500
CY2015 xoma Defined Contribution Plan Maximum Annual Contribution Per Employee Over50 Years Old Amount
DefinedContributionPlanMaximumAnnualContributionPerEmployeeOver50YearsOldAmount
24000
CY2014 xoma Defined Contribution Plan Maximum Annual Contribution Per Employee Over50 Years Old Amount
DefinedContributionPlanMaximumAnnualContributionPerEmployeeOver50YearsOldAmount
23000
CY2015 xoma Defined Contribution Plan Age Required For Catch Up Contribution Minimum
DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum
P50Y
CY2014 xoma Defined Contribution Plan Age Required For Catch Up Contribution Minimum
DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum
P50Y
CY2015 xoma Defined Contribution Plan Employer Matching Contribution Percent Of Employer Salary Deferred Maximum
DefinedContributionPlanEmployerMatchingContributionPercentOfEmployerSalaryDeferredMaximum
0.50
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
800000
CY2014 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1000000
CY2013 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
900000
CY2015 xoma Defined Contribution Plan Cost Recognized And Paid Through Issuance Of Common Shares Percentage
DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage
1.00
CY2014 xoma Defined Contribution Plan Cost Recognized And Paid Through Issuance Of Common Shares Percentage
DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage
1.00
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-124058000
CY2014 xoma Amount Of Dilutive Securities For Revaluation Of Contingent Warrant Liabilities
AmountOfDilutiveSecuritiesForRevaluationOfContingentWarrantLiabilities
-39512000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-20606000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-77813000
CY2013 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-124058000
CY2014 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
7898000
CY2014Q4 us-gaap Share Price
SharePrice
4.94
CY2013Q4 xoma Capital Units Issued Upon The Underwriters Allotment Option
CapitalUnitsIssuedUponTheUnderwritersAllotmentOption
1425000
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
18165000
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
21768000
CY2015Q4 xoma Contractual Obligation Estimated Milestone Payments
ContractualObligationEstimatedMilestonePayments
57700000
CY2015Q4 xoma Operating Leases Number Of Successive Renewal Options
OperatingLeasesNumberOfSuccessiveRenewalOptions
2
CY2015 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P5Y
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3631000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3732000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3842000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3956000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
4060000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
6794000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
26015000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
3700000
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
3500000
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
3500000
CY2015 xoma Capital Leases Lease Term
CapitalLeasesLeaseTerm
P3Y
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
131000
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
116000
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
72000
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
319000
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
37000
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
282000
CY2015Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
109000
CY2015Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
173000
CY2015 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2015Q1 us-gaap Revenues
Revenues
2651000
CY2015Q2 us-gaap Revenues
Revenues
2539000
CY2015Q3 us-gaap Revenues
Revenues
2074000
CY2015Q4 us-gaap Revenues
Revenues
48183000
CY2015Q3 us-gaap Restructuring Charges
RestructuringCharges
2561000
CY2015Q4 us-gaap Restructuring Charges
RestructuringCharges
1138000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
25224000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
24752000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
23191000
CY2015Q4 us-gaap Operating Expenses
OperatingExpenses
18305000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-22573000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22213000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23678000
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
28740000
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
855000
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1546000
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
23198000
CY2015Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3389000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-21718000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-23759000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-480000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
25351000
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2015Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2015Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2014Q1 us-gaap Revenues
Revenues
3410000
CY2014Q2 us-gaap Revenues
Revenues
5973000
CY2014Q3 us-gaap Revenues
Revenues
5136000
CY2014Q4 us-gaap Revenues
Revenues
4347000
CY2014Q1 us-gaap Restructuring Charges
RestructuringCharges
84000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
26800000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
24750000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
25589000
CY2014Q4 us-gaap Operating Expenses
OperatingExpenses
23475000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-23474000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18777000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20453000
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-19128000
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
18787000
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6880000
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6054000
CY2014Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11810000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-4687000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-11897000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-14399000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-7318000
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12

Files In Submission

Name View Source Status
0001564590-16-014295-index-headers.html Edgar Link pending
0001564590-16-014295-index.html Edgar Link pending
0001564590-16-014295.txt Edgar Link pending
0001564590-16-014295-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201603091951098099003.jpg Edgar Link pending
g201603091951102109421.jpg Edgar Link pending
g201603091951279738989.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xoma-10k_20151231.htm Edgar Link pending
xoma-20151231.xml Edgar Link completed
xoma-20151231.xsd Edgar Link pending
xoma-20151231_cal.xml Edgar Link unprocessable
xoma-20151231_def.xml Edgar Link unprocessable
xoma-20151231_lab.xml Edgar Link unprocessable
xoma-20151231_pre.xml Edgar Link unprocessable
xoma-ex1030_1091.htm Edgar Link pending
xoma-ex1031_1092.htm Edgar Link pending
xoma-ex1032_887.htm Edgar Link pending
xoma-ex1063_818.htm Edgar Link pending
xoma-ex1064_1371.htm Edgar Link pending
xoma-ex1065_817.htm Edgar Link pending
xoma-ex211_10.htm Edgar Link pending
xoma-ex231_9.htm Edgar Link pending
xoma-ex311_8.htm Edgar Link pending
xoma-ex312_7.htm Edgar Link pending
xoma-ex321_6.htm Edgar Link pending
xoma-ex991_1370.htm Edgar Link pending